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summary
The objective of this study was to determine long-term effectiveness and safety of 1st biological treatment 
(BT) in a cohort of 301 juvenile idiopathic arthritis (JIA) patients (pts), non-responders to disease-modifying 
antirheumatic drugs (DMARDs), in terms of drug survival (continuation rate on therapy) and to identify the 
baseline predictors of treatment discontinuation.
Each JIA pt enrolled in BT is prospectively assessed at the start of treatment and then every 2 months for the 
evaluation of safety and efficacy according to ACR-Pedi30 criteria. All clinical charts of pts who started a BT 
between November 1999 and July 2010 have been reviewed. Survival analysis methods suitable for compet-
ing risks were used to study time to drug discontinuation due to disease control (defined according to Wallace 
criteria) or failure [adverse event (AE), lack of efficacy (LaE) or loss of efficacy (LoE) according ACR-Pedi30].
A number of 301 JIA pts, non-responders or intolerant to DMARDs and treated with one or more cycles of 
BT, were identified. Median disease duration, from onset to the beginning of 1st BT, was 7.8 years (interquartil 
range 2.21-15.1). In total, there were 294 1st corses with anti-TNF agents, 5 with abatacept and 2 with anakinra. 
A number of 298 pts were included in the analysis for drug discontinuation (3 pts with no follow-up data after 
their first dose of BT were excluded). The median follow-up on treatment, before discontinuation due to every 
cause, was 53.7 months (range 0.45-124.45). One hundred and sixty-five pts discontinued BT: 27 due to disease 
control, 135 because of failure (78 AEs, 12 LaE and 45 LoE), 3 pts temporarily stopped for pregnancy. Among 
135 pts who discontinued for failure, 117 switched to a 2nd BT. Among 27 pts who discontinued due to remis-
sion, 13 pts restarted on BT for relapse of disease activity (10 pts restarted with the same BT, 3 switched to a dif-
ferent one). Predictors of discontinuation due to AE were female gender (P=0.01) and longer disease duration 
(P=0.02). Predictors of discontinuation due to LaE or LoE were systemic onset and polyarthritis FR positive 
(vs other JIA subtypes) (P<0.05) and use of mAb-anti-TNF (vs sTNFR) (P=0.02). Predictors of discontinuation 
due to inactive disease were male gender and shorter disease duration (P<0.05).
Although only few pts discontinued BT due to a complete and persistent disease control, the majority of them 
remained on BT for a long time, suggesting that in our cohort of JIA pts, affected by a severe long lasting refrac-
tory disease, BT was globally well tolerate and efficacious in controlling the disease.
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n	 INTRODUCTION 
The introduction of TNF-blocking agents since 2000 has tremendously changed 
the treatment of juvenile idiopathic arthri-
tis (JIA). From randomized controlled tri-
als there is evidence that TNF-blocking 
agents are efficacious and safe, but data on 
their long-term expected and unexpected 
effects remain relatively scarce. 
Longer follow-up of TNF-blocking agents 
is necessary in order to report the occur-
rence of adverse events (AE). To this aim, 
an observational study is an appropriate 
design (1). 
There have been few reports of biological 
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treatment (BT) discontinuation rates and 
factors associated with discontinuation (2-
4). The aim of this study is to collect long-
term outcome data on children receiving 
biological agents for JIA in terms of drug 
survival and to explore the reasons for bio-
logical therapy discontinuation. 
n	 MATERIALS AND METHODS
Since November 1999 to July 2010, all JIA 
patients (pts) who started for the first time 
a BT at Pediatric Unit of Rheumatology 
Department of Gaetano Pini Institute, Uni-
versity of Milan, have been included in this 
prospective cohort study. 
At baseline and at each visit, the following 
assessments were performed: the number 
and site of active joints, the number and site 
of limited joints, erythrocyte sedimentation 
rate and/or C-reactive protein, patient vi-
sual analogue scales (VAS 0-100 mm) for 
general health and for pain, physician VAS 
for disease activity and the CHAQ Disabili-
ty Index. Treatment response to methotrex-
ate (MTX) and previous disease-modifying 
antirheumatic drugs (DMARDs), and the 
eligibility for BT, was judged according to 
the ACR-Pedi30 response criteria (5). After 
starting the treatment, follow-up data were 
collected every 2 months. AE data were 
collected as part of monitoring. 
Discontinuation was defined as cessa-
tion of the drug because of disease con-
trol according to Wallace criteria [inactive 
disease (ID) (6) or clinical remission on 
medication (CRM)], or failure. Failure was 
defined by AEs or inefficacy according to 
ACR-Pedi30, inefficacy was defined as: 
lack of efficacy (LaE), after a minimum pe-
riod on therapy of at least 6 weeks, or loss 
of efficacy (LoE) after a variable period of 
successful treatment. 
n	 STATISTICAL ANALYSIS
Time to discontinuation was defined ac-
cording to the date of stop/switched or to 
the last follow-up on therapy. Statistical 
analysis was performed by methods suit-
able for the presence of competing events 
in survival analysis. In the competing risks 
setup, in fact, patients during the follow-up 
are exposed to the risk of stopping/switch-
ing BT for different causes, also before 
achieving CRM. Crude cumulative inci-
dences (CCI) were estimated using a prop-
er non-parametric estimator in the compet-
ing events framework and were compared 
by the Gray test (7). An extension of Cox 
proportional hazards models which the risk 
of competing events is taken into account 
was used to estimate the specific hazard for 
CCI with 95% CI (8).
Beside kind of BT, and concomitant treat-
ment with DMARDs the following pre-
dictors were considered in the statistical 
analysis: gender, ILAR category, age at 
symptom onset, age at and disease duration 
before starting BT.
In the multivariable analysis, all variables 
above mentioned were firstly included. In 
the final model, gender and kind of BT 
were always retained, together with other 
predictors only if they were statistically sig-
nificant (P<0.05) or if they showed moder-
ate evidence of association (P≤0.1) with the 
outcome of interest. 
n	 RESULTS
On the whole 301 JIA pts treated with one 
or more courses of biological drugs were 
enrolled. Main demographic and baseline 
characteristics are summarized in Table I.
The majority of them (57.8%) were ini-
tially treated with etanercept (174). In total 
294 pts were treated with anti-TNF agents 
as the first course of BT, 5 with abatacept 
and 2 with anakinra. 
In total 580 different courses of biological 
agents were administered to 301 pts. The 
median number of treatments for patient 
was 1 (range 1-8), ranging from 1 in per-
sistent oligoarticular JIA to 2 and 1.5 in 
systemic onset JIA (so-JIA) and psoriatic 
arthritis respectively. 
More than half of treatments (323, 55.7%), 
were administered in monotherapy, the re-
maining were given in combination with 
one or more DMARDs. MTX (268) was 
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the most frequently concomitant treatment, 
43 BT were associated with leflunomide, 
39 with cyclosporin, 25 with sulfasalazine, 
21 with OH-chloroquine, 12 with azathio-
prine and 4 with gold salt.
Causes of discontinuation of the 1st bio-
logical treatment and follow-up after dis-
continuation
All 301 scrutinized patients, but 3 with no 
available follow-up data after their first 
dose of BT, were included in the analysis 
for drug discontinuation. The median fol-
low-up time on treatment, as estimated by 
Shemper et al. (9) was about 53.7 months 
(range 0.45-124.45). Figure 1 shows the 
Kaplan-Meier analysis.
In total 165/298 pts discontinued the ther-
apy (Table II): 
- 135 discontinued for failure, in particu-
lar:
1) 78 for AEs (CCI 34.58%),
2) 12 for LaE (CCI 4.05%),
3) 45 for LoE (CCI 21.67%);
Table I - Demographic and baseline characteristics for each juvenile idiopathic arthritis subtype.
JIa subtype Gender F 
(%)
uveitis 
(%)
Onset age (years) 
median (1st and 3rd 
quartiles)
age of 
initiation of BT 
(years) median 
(1st and 3rd 
quartiles)
Disease 
duration of 
JIa (years) 
median 
(1st and 3rd 
quartiles)
Treatment 
duration at 
last follow-
up (months) 
median 
(1st and 3rd 
quartiles)
Systemic arthritis
50 (16.6%)
31
(62.0%)
0
(0%)
5.8
(3.98-12-3)
16.7
(10.66-23.95)
8.3
(3.03-16.07)
12.6
(5.14-47.10)
Persistent 
oligoarticular
50 (16.6%)
35
(70.0%)
22
(44.0%)
3.0
(1.99-6.42)
12.4
(6.83-17.95)
7.5
(3.35-11.38)
23.7
(12.23-43.54 )
Extended 
oligoarticular
87 (28.9%)
73
(83.9%)
24
(27.6%)
2.7
(1.57-6.44)
13.5
(8.74-21.28)
8.8
(4.17-17.60)
25.3
(12.38-43.36)
RF negative 
poliarticular
58 (19.3%)
42
(72.4%)
7
(12.1%)
5.9
(2.72-9.60)
13.8
(8.46-19.18)
7.5
(1.31-11.55)
23.7
(11.66-50.96)
RF positive 
poliarticular
28 (9.3%)
23
(82.1%)
0
(0%)
11.9
(10.02-14.5)
17.4
(14.76-20.11)
5.1
(0.71-9.89)
19.1
(10.28-49.71)
Entesitis related 
arthritis
18 (6.0%)
7
(38.9%)
1
(5.6%)
11.7
(9.54–13.10)
18.5
(14.88-23.82)
7.3
(2.83-10.77)
32.7
(12.85-60.7)
Psoriatic arthritis
10 (3.3%)
6
(6.0%)
2
(22.2%)
8.2
(3.18-9.99)
23.8
(16.98-30.74)
14.5
(8.03-22.62)
37.4
(22.17-47.18)
Total
301
218
(72.4%)
56
(18.6%)
5.3
(2.37-11.11)
15.1
(9.39-21.07)
7.8
(2.21-15.1)
24.0
(10.84-48.00)
JIA, juvenile idiopathic arthritis; BT, biological treatment.
Figure 1 - Kaplan-Meier survival analysis of bio-
logical therapy.
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- 27 (CCI 14.51%) discontinued for ID, 
after reaching CRM, but among these, 13 
restarted on a BT, for relapse of disease 
activity, after a median period free from 
biological drug of 6.6 months (range 2.4-
28.6);
- 3 pts (CCI 2.3%) temporarily stopped for 
pregnancy.
The majority of pts who suspended the 
1st biological approach for any reason 
(120/165), switched to a 2nd one (117 anti-
TNF and 3 non-anti-TNF). In details:
1) 64 out of the 78 pts who discontinued 
for AEs (12 of them after reaching 
CRM);
2) 53 out of the 57 pts who discontinued 
for failure, either for LoE 41 pts (6 after 
CRM) or for LaE 12 pts;
3) 3 pts out of 27 after stopping for ID, 
relapsed and switched to a 2nd different 
biological drug.
Seventeen pts discontinued for different 
reasons but then restarted with the same 
biological treatment (3 pts stopped during 
pregnancy and restarted after delivery, 10 
pts discontinued for ID but then relapsed 
and restarted). Twenty-eight pts defini-
tively stopped BT, 14 after failure (12 AEs, 
2 LoE) and 14 after reaching the state of 
CRM. The probability of discontinuation 
for ID and for the other causes is shown in 
Figure 2.
Discontinuation due to adverse events
Considering all first biological treatments, 
out of our 298 evaluated pts (during a glob-
al exposure to study drug of 800.13 pt/yrs), 
78 discontinued due to an AE after a medi-
an period of therapy of 14.7 months (range 
0.5-70.0). The rate of AEs was 0.097 AEs/
pt/yrs that means one withdrawal for AE 
every 10.27 pt/years. 
Among the 78 pts who failed the treatment 
for AEs, 62 were females: the rate of AEs 
Table II - Causes of discontinuation of 1st biological agent and follow-up.
Drug Follow-up Total
172 ETa 83 INFL 36 aDa 2 aNa 5 aBa stop restart switch
Causes Follow-up
AEs 
Stop biol. 9 2 1 12
Restarted 1 1 0 2
Switched 30 29 4 1 64
Total aEs 40 32 5 1 78
LaE
Stop biol. 0 0 0 0
Restarted 0 0 0 0
Switched 4 4 3 1 12
Total LaE 4 4 3 12
LoE 
Stop biol. 1 1 0 2
Restarted 2 0 0 2
Switched 16 20 4 1 41
Total LoE 19 21 4 45
ID 
Stop biol. 7 4 3 14
Restarted 8 1 1 10
Switched 3 0 0 3
Total ID 18 5 4 27
Pregnancy
Stop biol. 0 0 0 0
Restarted 1 2 0 3
Switched 0 0 0 0
Total 
pregnancy 1 2 3
Total 165 82 64 16 1 2 28 17 120 165
ETA, etanercept; INFL, infliximab; ADA, adalimumab; ANA, anakinra; ABA, abatacept; AEs, adverse 
events; LaE, lack of efficacy; LoE, loss of efficacy; ID, inactive disease.
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in female was 0.11 AEs/pt/yrs vs 0.07 in 
male, that means one withdrawal for AE 
every 9.0 pt/yrs in female vs every 15.1 pt/
yrs in male population.
Among the 78 pts who failed the treat-
ment for AEs, 15 were soJIA, and 63 were 
non-soJIA pts: the rate of AEs in soJIA pts 
was 0.13 AEs/pt/yrs vs 0.09 in non-soJIA, 
that means one withdrawal for AE every 
7.9 pt/yrs in soJIA vs every 10.8 pt/yrs in 
non-so-JIA population. soJIA suspended 
for AEs after a median period of therapy 
of 5.2 months (range 0.5-35.8), non-soJIA 
suspended for AEs after a median period of 
therapy of 19.4 months (range 0.9-70.0).
According to the disease duration, we con-
sidered 2 groups of pts: group I pts with a 
disease duration <5 yrs, group II pts with 
disease duration longer than 5 yrs. Pts who 
failed for AEs were respectively 18 out of 
108 and 60 out of 193. The rate of AEs was 
respectively 0.06 vs 0.12 AEs/pt/yrs [that 
means one withdrawal for AE every 15.9 vs 
8.6 pt/yrs respectively].
The only predictor entered in the final mul-
tivariable model, beside gender and kind 
of BT was disease duration before start-
ing treatment (HR for 5 yrs increase 1.17, 
P=0.02) (Table III). 
Discontinuation due to lack/loss of effi-
cacy
According to the study drug, we considered 
2 groups of pts: group I pts treated with the 
sTNFR, group II pts treated with mAb-
anti-TNF (infliximab and adalimumab). 
Pts who failed for inefficacy (LaE or LoE) 
were respectively: 23 out of 174 and 32 out 
of 120. The rate of failure was respectively: 
0.05 vs 0.11 failure/pt/yrs (that means one 
Figure 2 - Treatment discontinuation due to inactive disease, adverse events and loss of ef-
ficacy. 
Table III - Reported adverse events during 
biological treatment.
aE leading to withdrawal #TOT
Infusion reaction 23
Behavioral disorders 12
New onset/relapse/worsening of uveitis 12
Dermatological manifestations 8
Inflammatory bowel disease 7
Hematological manifestation (leukopenia, 
thrombocytopenia, anemia one case each)
3
Neurological manifestation (one headache, 2 
suspected demyelinating diseases)
3
Autoimmunity/lupus-like 2
Infections (one leading to MAS) 2
Ipertension 2
Injection site reaction 2
Macrohematuria 1
Menorrhagia 1
Total 78
AE, adverse event; MAS, macrophage-activation 
syndrome.
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withdrawal for inefficacy every 21.2 vs 9.5 
pt/years respectively).
According to ILAR categories, pts who 
failed for inefficacy (LaE or LoE) were re-
spectively 17 out of 50 with soJIA, 7 out 
of 28 seropositive polyarthritis, 11 out of 
58 seronegative polyarthritis, 4 out of 50 
persistent oligoarthritis, 12 out 87 extended 
oligoarthritis and 6 with other JIA. The rate 
of failure was respectively 0.14, 0.11, 0.07, 
0.03, 0.05, 0.06 failure/pt/yrs.
In the multivariate analysis, the only pre-
dictor entered the final model, beside gen-
der and kind of BT was the ILAR category. 
Pts treated firstly with mAb-anti-TNF pre-
sented significantly higher failure rate (HR 
mAb-anti-TNF vs sTNFR 1.9, P=0.02); 
about the ILAR category, pts with persis-
tent and extended oligoarthritis presented 
significantly lower failure rate (HR persis-
tent vs soJIA 0.23, P=0.01 and HR extend-
ed vs soJIA 0.34, P=0.008).
Discontinuation due to inactive disease/
remission
According to gender, pts who stopped 
treatment do to the achievement of ID or 
CRM were 11 out of 217 females vs 16 out 
of 84 males. The rate of discontinuation 
for ID/CRM was respectively: 0.02 vs 0.07 
ID-CRM/pt/yrs (that means one withdraw-
al for ID/CRM every 50.0 vs 15.1 pt/years 
respectively).
According to diagnosis groups, pts who 
stopped treatment do to the achievement of 
ID or CRM were 4 out of 50 soJIA (8.0%), 
23 out of 251 non-soJIA (9.2%). The fre-
quency of discontinuation for ID-CRM 
was similar in both groups: 0.037 vs 0.039 
discontinuation for ID-CRM/pt/yrs (that 
means one withdrawal for ID/CRM every 
29.7 vs 29.5 pt/years respectively).
According to study drug, pts who stopped 
treatment due to the achievement of ID 
or CRM were: 18 out of 174 treated with 
etanercept, 5 out of 83 treated with inflix-
imab, 4 out of 37 treated with adalimumab. 
The rate of discontinuation for ID-CRM 
was similar in pts treated with subcutane-
ous biological drugs: 0.04 and 0.05 events/
pt/yrs respectively with etanercept and 
with adalimumab (that means one with-
drawal for ID/CRM every 27.1 vs 19.2 pt/
years respectively). The rate of discontinu-
ation for ID-CRM in pts treated with inf-
liximab was 0.02 events/pt/yrs (that means 
one withdrawal for ID/CRM every 45.5 pt/
yrs).
Table IV - Results from both the univariate and the multivariable models.
Predictors adverse events Lack/loss of efficacy Inactive disease or complete remission
unadjusted Hr adjusted Hr unadjusted Hr adjusted Hr unadjusted Hr adjusted Hr
Gender (M 
vs F)
0.61 
(0.35-1.06)
0.62 
(0.35-1.10)
0.64 
(0.34-1.21)
0.59 
(0.29-1.16) 4.07 (1.9-8.69)
3.55
(1.61-7.84)
AntiTNF vs 
Etanercept
1.37 
(0.87-2.16)
1.12 
(0.69-1.82)
2.05 
(1.20-3.5)
1.90
(1.08-3.35) 0.62 (0.28-1.34)
1.00 
(0.44-2.27)
Other vs 
Etanercept
0.81 
(0.09-6.80)
0.81 
(0.09-7.16)
3.41 
(0.80-14.4)
2.36 
(0.53-10.59) - -
Disease 
duration 
(5 years)
1.19 
(0.56-2.52)
1.17 
(1.16-1.18)
1.09 
(0.51-2.32) -
0.605 
(0.60-0.61)
0.65 
(0.645-0.655)
OligoPer 
vs Sys
0.85 
(0.40-1.77) -
0.24 
(0.08-0.73)
0.23 
(0.08-0.73)
1.06
 (0.24-4.67)
-
OligoExt 
vs Sys
1.31 
(0.74-2.33)
- 0.36 
(0.17-0.75)
0.34
 (0.15-0.76)
0.94 
(0.27-3.30)
-
PolyRFpos. 
vs Sys
0.42 
(0.12-1.46)
- 0.82 
(0.34-2.0)
0.77 
(0.31-1.89)
1.70 
(0.41-7.07)
-
PolyRFneg. 
vs Sys
0.95 
(0.48-1.87)
- 0.52 
(0.24-1.14)
0.56 
(0.24-1.28)
1.87 
(0.58-5.99)
-
Other 
vs Sys
0.76 
(0.08-6.63)
- 0.55 
(0.22-1.36)
0.54 
(0.22-1.31)
1.39 
(0.31-6.29)
-
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No pts treated with non-anti-TNF drugs 
during their first course discontinued due 
to disease control, and then were excluded 
when fitting multivariable model.
In the multivariate analysis the only predic-
tor entered the final model for discontinua-
tion due to inactive disease are, beside gen-
der and BT, was disease duration. In partic-
ular, males (HR 3.5, P=0.002) and pts with 
shorter disease duration before starting BT 
shows higher remission rate (HR for 5 yrs 
1.54, P=0.05).
Results from both the univariate and the 
multivariable models were summarized in 
Table IV.
n	 DISCUSSION
Since the beginning of 2000, on the basis 
of controlled trials that proved the efficacy 
and safety of TNFa blockade in JIA, this 
therapeutical approach has been extensive-
ly applied in clinical practice. Biologics 
have revolutionized the treatment of JIA 
due to their efficacy, speed of onset and tol-
erability. Overall tolerability of anti-TNFa 
therapy in JIA was good in ours (1, 10) as in 
many other studies, but data on their long-
term efficacy and safety remain relatively 
scarce. There have been few reports of BT 
discontinuation rates and factors associated 
with discontinuation (2-4). The aim of this 
study is to collect long-term outcome data 
on children receiving biological agents for 
JIA in terms of drug survival and to explore 
the reasons for biological therapy discon-
tinuation. 
Our cohort of 301 pts treated with BT rep-
resents the more severe spectrum of JIA, 
those who failed to tolerate or respond to 
MTX and previous DMARDs and suffer-
ing from long lasting disease.
Drug survival data from this 10-year-follow 
up study, in a real-life setting of unselected 
population, proves that more than 50% of 
pts continue the treatment at 36 months, 
suggesting that the majority of them find 
biological drug tolerable and effective. Dif-
ferent drug survival data have been report-
ed by etanercept European registries (2-4, 
11). Nevertheless, due to the difference in 
patients’ numbers, duration of follow-up, 
and drug administered, a comparison with 
the European registries is difficult.
The majority of pts who suspended the 
1st biological approach for any reason 
(120/165) switched to a second biologi-
cal treatment, more frequently a further 
TNF-a blocking agent.
The most common reasons for stopping 
BT in our cohort were AEs. It is interesting 
that infusion reactions have been the most 
frequently reported AEs but infliximab 
therapy was not a predictor of discontinua-
tion for AEs. Data from Finnish registry (4) 
showed that infliximab was more often dis-
continued because of AEs, even if, overall 
treatment survival of etanercept and inflix-
imab in JIA was comparable. In our study a 
significant lower chance to stop due to AEs 
was observed in patients with shorter dis-
ease duration before starting BT, moderate 
evidence was also found for male gender.
In all the European cohorts (2-4, 12) sys-
temic JIA has been previously reported to 
be associated with etanercept inefficacy. 
Also in our study the probability of discon-
tinuation for inefficacy (lack or loss of ef-
ficacy) was associated with systemic JIA. 
Furthermore, in our study, the probability 
of discontinuation for inefficacy was as-
sociated with the use of mAb anti-TNF vs 
sTNFR. 
Our results, based on a large number of pts, 
showed that only few patients (#27) sus-
pended for disease control. Nevertheless, 
136 of our pts reached the CRM but in the 
majority of them, according to our clini-
cal approach/judgment, to avoid a possible 
relapse, we preferred to maintain a long 
lasting treatment. Indeed half of patients 
(13/27), who stopped for ID, restarted 
therapy because of relapse of disease after 
a median period free from biological drug 
of 6.6 months. Male gender and earlier ini-
tiation of BT increased the chance to reach 
ID/CRM and to stop the treatment for this 
reason. This has been already observed in 
other European cohorts (11), therefore we 
suggest that an effective BT should be of-
fered within a narrow time period from the 
disease onset. No statistically difference 
was found between ILAR subtypes. 
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In conclusion, while the study confirms 
that BT is globally well tolerate and effec-
tive in JIA, the probability to withdrawal 
for disease control is low and associated 
with shorter disease duration at the begin-
ning of treatment. However, the prolonged 
use of BT provides objective surrogate in-
formation of clinical benefit during first 
biological course.
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tional Congress, Milano, 2012.
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